Public-registry trials using Xanomeline/Trospium Chloride that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Schizophrenia | PHASE3 | 61 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →